Three scientists from Bengaluru, who led a team of global researchers looking for an antimalarial drug, have found a fast-killing solution. After completing some tests, it'll go in for clinical trials on humans. That this drug has the potential to cure the dreaded disease in one dose makes it more attractive to healthcare providers. The Bengaluru solution — Triaminopyrimidine (TAP) — comes with many advantages over existing drugs.
Vasan Sambandamurthy, one of the senior authors of the research paper, said: "It's a fast-killing and long-acting antimalarial clinical candidate. TAP acts exclusively on the blood stage of Plasmodium falciparum (the stage responsible for clinical symptoms) in a relevant mouse model. This candidate is equally active against causative agent Plasmodium vivax." He added, "The compound has shown good safety margins in guinea pigs and rats. With a predicted…
